drug
as of 2026-07-01AQW051 2 mg (single and multiple doses)
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Novartis Pharmaceuticals
1 trials in the graph
Synthesized from structured facts only — each point cited above.
Mechanism & identity
Modality
small molecule
Indications
Investigational (via trials)
Trials
1
Effect of AQW051 on Cognitive Function in Patients With Chronic Stable Schizophrenia
NCT01163227Phase 2Completed
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
company
trial
indication
indication
indication
indication
indication